O
BHVN

OrbiMed’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

OrbiMed’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,000
Closed -$1.29M – 161
2018
Q1 		$1.29M Buy
+50,000
New +$1.49M 0.02% 132

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

OrbiMed's BHVN Position: Q4 2022 in Review

OrbiMed sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 170,769 shares — an estimated $25.8K sold.

OrbiMed first reported a position in BHVN in Q1 2022 and held it in 3 quarters. The position peaked at $85.3M in Q1 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • OrbiMed reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • OrbiMed sold 170,769 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $25.8K.
  • OrbiMed first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022 and held it in 3 quarters.
  • OrbiMed's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $85.3M in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.